Pipeline coverage: test concentration before trusting the multiple

The quarter has three times the pipeline needed to cover the remaining target. The headline is reassuring. Then someone asks what happens if the largest opportunity moves, and the room starts rebuilding the forecast from memory. The apparent cushion depends on deals the team has never considered together.

Before trusting a pipeline coverage multiple, inspect how much value sits in the largest opportunities and how much credible depth remains beneath them. Show the largest-deal shares, the distribution of the remaining book and the time available to replace a lost opportunity. The purpose is to decide whether the current pipeline shape supports the plan and where leadership attention or future pipeline investment belongs.

Coverage answers a question about the quantity of opportunity available. Concentration asks how fragile that quantity is. Neither substitutes for a forecast. A portfolio can have substantial pipeline and still offer very few credible ways to make the quarter.

Begin with one honest denominator

Agree what the multiple divides before discussing whether it is healthy. For an in-quarter recovery decision, compare eligible open pipeline with the remaining target after actual attainment. Use the same currency, revenue definition, segment and period on both sides. Annual contract value against a quarterly recognized-revenue target creates a precise-looking answer to the wrong question.

Keep new business, expansion and renewals distinct when their buying paths differ. If a leader wants a combined view, show the components beneath it. A renewal awaiting routine processing is not interchangeable with a new customer still deciding whether to change.

Eligibility also matters. A close date inside the quarter is a record value, not proof that the buyer can complete the work by then. Apply the team’s existing qualification and timing rules. Put disputed amounts or unsupported dates in a visible exception group so the coverage number does not silently include a second set of assumptions.

A fictional quarter with shallow replacement depth

Consider a fictional software company with a $2 million remaining bookings target and $6 million of eligible open pipeline: 3.0 times coverage. All figures below are illustrative. The three largest deals are worth $1.2 million, $900,000 and $600,000. Together they represent $2.7 million, or 45% of open pipeline. The remaining $3.3 million is spread across smaller opportunities.

If the largest deal moves outside the quarter, in-period pipeline falls to $4.8 million and coverage becomes 2.4 times. If the largest three move, it falls to $3.3 million and 1.65 times. These are inventory sensitivity checks, not revenue predictions. They do not say that every remaining deal will close or assign probabilities to the possibilities.

Now inspect the depth beneath the top three. Suppose the remaining $3.3 million consists of eleven opportunities worth $200,000 each and twenty-two worth $50,000 each. The $1.2 million largest deal represents the same face value as six of those midsize opportunities or twenty-four smaller ones. There are only twenty-two smaller opportunities in the current book. That comparison makes the scale of the dependence easier to discuss without pretending the deals are interchangeable.

The CRO should not ask sellers to manufacture six replacement wins. Their stages, customer timelines and probabilities differ. The useful question is whether there is a plausible path through the rest of the book if one large purchase changes timing. If there is not, leadership needs to acknowledge the exposure and develop the next period’s pipeline deliberately rather than treating a long tail of records as an automatic cushion.

Read the shape of the book alongside the strategy

Start with the largest one, three and five opportunities as a share of the eligible book. Show the number and value of the remaining opportunities by the few deal-size bands that match the business. Averages alone can hide the difference between a repeatable mid-market motion and a quarter dominated by a few enterprise purchases.

Compare that distribution with the plan. If the business deliberately moved upmarket, higher concentration may be an expected consequence. Leadership should test whether the target, specialist capacity and tolerance for quarterly variation changed with the strategy. A larger average contract is not free replacement for the volume the company no longer pursues.

Look at concentration within relevant segments too. A diversified company-wide total can hide a region whose entire target rests on one customer. Conversely, splitting a small book into many tiny groups can exaggerate ordinary variation. Use the segment only when a leader can make a different operating decision for it.

Keep common-cause exposure as a separate analytical question. Several otherwise modest deals can depend on the same external event; that belongs in a dependency scenario. This concentration review establishes how much of the plan rests on a few individual purchases and whether the rest of the book offers a credible alternative path.

Choose the response that can still change the period

The stress test should produce a short decision list. A buyer-confirmed evaluation blocked by internal capacity may justify moving a specialist. A deal with no established approval path needs a customer conversation. A portfolio that is simply too small may require an expectation change; asking marketing for last-minute demand will not compress a long buying cycle.

For the fictional company, the CRO could examine the eleven midsize opportunities with their managers. Which have a buyer-supported path within the period, and which remain early exploration? The purpose is to understand credible depth, not move close dates to make the smaller deals appear ready. If the remaining period is shorter than the normal buying journey, newly created pipeline belongs in the future plan rather than the current recovery story.

The CRO also needs a statement about the $1.2 million deal. If losing its timing would materially change the quarter, name the buyer fact that needs verification and the date on which the forecast view will change if it remains unresolved. Repeating that the deal is important adds pressure; defining the missing evidence gives the seller a useful job.

Protect the future while handling the present. Pulling every capable person into the largest current deal can worsen concentration in the next quarter by starving earlier opportunities. State which work is displaced and when it will resume. A recovery choice should be assessed across both periods, even when the immediate call dominates the meeting.

Prepare a compact concentration note

A useful note has the remaining target, eligible pipeline, largest-one and largest-three shares, the size distribution beneath them and the buyer-supported timing of that remaining book. Include the concentration by one material segment where it changes the decision. Keep the baseline and record identifiers so the reviewer can inspect which opportunities carry the conclusion.

Do not introduce a universal red threshold such as “anything above 30% is bad.” A threshold should reflect the business’s deal distribution, cycle length and tolerance for volatility. Start with whether the dependence changes a real staffing, spending or forecast decision. That is the reason to escalate.

Revisit the note when the underlying evidence changes, rather than adding another standing meeting. A newly qualified opportunity, completed evaluation or moved customer decision may change the shape of the book. Preserve the earlier view long enough to learn whether the team noticed concentration while it still had useful choices.

Record both the action on the current quarter and the investment for the next one. Targeted executive attention may be appropriate for the largest opportunity now; building a more balanced future book is a different job with a different owner and lag. Keeping both visible prevents a recurring concentration problem from being managed only through quarter-end intervention.

Use prepared analysis to make room for the difficult conversation

RevTech’s Analyst Agent supports recurring CRM questions about pipeline, coverage, conversion and change, with sources and supporting records. A bounded starting question is: “Which opportunities account for the largest share of this quarter’s eligible pipeline, and what changed since last week?” Leadership can inspect that answer before deciding where a deeper opportunity review or future pipeline investment is warranted.

The agent’s scheduled preparation does not establish buyer commitment, declare a smaller deal a viable substitute or choose the CRO’s risk tolerance. Agree the available fields, scope and review requirements first. Missing timing evidence remains a question for the account team, not a fact the analysis should invent.

At the next coverage review, ask one question before accepting the multiple: which few events would make this number stop being reassuring? Answer it with records, then leave the meeting with a decision about those events. That is when coverage becomes useful to the people carrying the quarter.